94 related articles for article (PubMed ID: 1571047)
1. HLA-A11 in renal allograft recipients with skin cancer.
McGregor JM; Reddi G; MacDonald D; Vaughan RW; Welsh KI
J Invest Dermatol; 1992 Feb; 98(2):261-2. PubMed ID: 1571047
[No Abstract] [Full Text] [Related]
2. On a possible protective effect of HLA-A11 against skin cancer and keratotic skin lesions in renal transplant recipients.
Bouwes Bavinck JN; Kootte AM; Van Der Woude FJ; Vandenbroucke JP; Vermeer BJ; Claas FH
J Invest Dermatol; 1991 Aug; 97(2):269-72. PubMed ID: 1649229
[TBL] [Abstract][Full Text] [Related]
3. HLA-A11-associated resistance to skin cancer in renal-transplant recipients.
Bavinck JN; Kootte AM; van der Woude FJ; Vandenbroucke JP; Vermeer BJ; Claas FH
N Engl J Med; 1990 Nov; 323(19):1350. PubMed ID: 2215624
[No Abstract] [Full Text] [Related]
4. Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia.
Bouwes Bavinck JN; Claas FH; Hardie DR; Green A; Vermeer BJ; Hardie IR
J Invest Dermatol; 1997 May; 108(5):708-11. PubMed ID: 9129219
[TBL] [Abstract][Full Text] [Related]
5. Relation between skin cancer and HLA antigens in renal-transplant recipients.
Bouwes Bavinck JN; Vermeer BJ; van der Woude FJ; Vandenbroucke JP; Schreuder GM; Thorogood J; Persijn GG; Claas FH
N Engl J Med; 1991 Sep; 325(12):843-8. PubMed ID: 1875968
[TBL] [Abstract][Full Text] [Related]
6. Skin cancers and HLA frequencies in renal transplant recipients.
Czarnecki D; Watkins F; Leahy S; Dyall-Smith D; Levis A; Nicholson I; Tait B
Dermatology; 1992; 185(1):9-11. PubMed ID: 1638083
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen type as a risk factor for nonmelanomatous skin cancer in patients after renal transplantation.
Bock A; Bliss RL; Matas A; Little JA
Transplantation; 2004 Sep; 78(5):775-8. PubMed ID: 15371688
[TBL] [Abstract][Full Text] [Related]
8. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer.
Glover MT; Bodmer J; Bodmer W; Kennedy LJ; Brown J; Navarrete C; Kwan JT; Leigh IM
Eur J Cancer; 1993; 29A(4):520-4. PubMed ID: 8435203
[TBL] [Abstract][Full Text] [Related]
9. Characterization of kidney-specific peptides and their role in renal allograft rejection.
Poindexter NJ; Naziruddin B; Oppat W; Flye MW; Mohanakumar T
Transplant Proc; 1995 Feb; 27(1):900-2. PubMed ID: 7879223
[No Abstract] [Full Text] [Related]
10. Quantification of plasmacytoid dendritic cells and type 1 myeloid dendritic cells in peripheral blood of renal transplant recipients with and without squamous cell carcinoma.
Sandvik LF; Vogelsang P; Leivestad T; Jonsson R; Appel S
Acta Derm Venereol; 2012 Nov; 92(6):623-4. PubMed ID: 22378032
[No Abstract] [Full Text] [Related]
11. p53-specific serum antibodies are not associated with a history of skin carcinoma in renal transplant recipients and immunocompetent individuals.
de Graaf YG; Schiefer D; Redeker A; Vermeer BJ; Bavinck JN; Willemze R; de Gruijl FR; Van der Burg SH
J Dermatol Sci; 2005 Jun; 38(3):228-30. PubMed ID: 15927816
[No Abstract] [Full Text] [Related]
12. Serologic allogeneic chimerism.
McDonald JC; Adamashvili I; Zibari GB; Aultman DF; Mancini MC; McMillan RW; Gelder FB
Transplantation; 1997 Sep; 64(6):865-71. PubMed ID: 9326412
[TBL] [Abstract][Full Text] [Related]
13. Analysis of T-cell receptor V beta gene usage in T cells infiltrating human renal allografts.
Gecim IE; Christmas SE; Flanagan BF; Wheatcroft NJ; Brew R; Bakran A; Sells RA
Transplant Proc; 1993 Feb; 25(1 Pt 1):75-6. PubMed ID: 8438467
[No Abstract] [Full Text] [Related]
14. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
[TBL] [Abstract][Full Text] [Related]
15. Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study.
Tisch M; Kyrberg H; Weidauer H; Mytilineos J; Conradt C; Opelz G; Maier H
Laryngoscope; 2002 Apr; 112(4):651-7. PubMed ID: 12150518
[TBL] [Abstract][Full Text] [Related]
16. Soluble HLA class 1 antigens in kidney allograft recipients.
Drouet M; Petit B; Peyronnet P; Aussel L; Venot J; Leroux-Robert C; Fauchet R
Transplant Proc; 1995 Apr; 27(2):1671. PubMed ID: 7725446
[No Abstract] [Full Text] [Related]
17. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern.
Keller B; Braathen LR; Marti HP; Hunger RE
Swiss Med Wkly; 2010; 140():w13036. PubMed ID: 20652847
[TBL] [Abstract][Full Text] [Related]
18. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
19. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients.
Bavinck JN; Gissmann L; Claas FH; Van der Woude FJ; Persijn GG; Ter Schegget J; Vermeer BJ; Jochmus I; Müller M; Steger G
J Immunol; 1993 Aug; 151(3):1579-86. PubMed ID: 8393047
[TBL] [Abstract][Full Text] [Related]
20. HLA-A antigen incompatibility and HLA-B antigen compatibility associated with enhanced kidney allograft survival in blood-transfused patients.
Bućin D
Exp Clin Immunogenet; 1986; 3(3):138-44. PubMed ID: 3274633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
